Literature DB >> 28755801

International trends in antipsychotic use: A study in 16 countries, 2005-2014.

Óskar Hálfdánarson1, Helga Zoëga2, Lise Aagaard3, Miquel Bernardo4, Lena Brandt5, Anna Coma Fusté6, Kari Furu7, Kristina Garuoliené8, Falk Hoffmann9, Krista F Huybrechts10, Luuk J Kalverdijk11, Koji Kawakami12, Helle Kieler5, Takuya Kinoshita12, Melisa Litchfield13, Soffy C López14, Jorge E Machado-Alba14, Manuel E Machado-Duque14, Mufaddal Mahesri10, Prasad S Nishtala15, Sallie-Anne Pearson13, Johan Reutfors5, Leena K Saastamoinen16, Izumi Sato12, Catharina C M Schuiling-Veninga17, Yu-Chiau Shyu18, Svetlana Skurtveit7, Hélène Verdoux19, Liang-Jen Wang20, Corinne Zara Yahni6, Christian J Bachmann21.   

Abstract

The objective of this study was to assess international trends in antipsychotic use, using a standardised methodology. A repeated cross-sectional design was applied to data extracts from the years 2005 to 2014 from 16 countries worldwide. During the study period, the overall prevalence of antipsychotic use increased in 10 of the 16 studied countries. In 2014, the overall prevalence of antipsychotic use was highest in Taiwan (78.2/1000 persons), and lowest in Colombia (3.2/1000). In children and adolescents (0-19 years), antipsychotic use ranged from 0.5/1000 (Lithuania) to 30.8/1000 (Taiwan). In adults (20-64 years), the range was 2.8/1000 (Colombia) to 78.9/1000 (publicly insured US population), and in older adults (65+ years), antipsychotic use ranged from 19.0/1000 (Colombia) to 149.0/1000 (Taiwan). Atypical antipsychotic use increased in all populations (range of atypical/typical ratio: 0.7 (Taiwan) to 6.1 (New Zealand, Australia)). Quetiapine, risperidone, and olanzapine were most frequently prescribed. Prevalence and patterns of antipsychotic use varied markedly between countries. In the majority of populations, antipsychotic utilisation and especially the use of atypical antipsychotics increased over time. The high rates of antipsychotic prescriptions in older adults and in youths in some countries merit further investigation and systematic pharmacoepidemiologic monitoring.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Adult; Aged; Antipsychotic agents; Internationality; Minors; Pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 28755801     DOI: 10.1016/j.euroneuro.2017.07.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  51 in total

1.  Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016.

Authors:  Mikkel Højlund; Anton Pottegård; Erik Johnsen; Rune A Kroken; Johan Reutfors; Povl Munk-Jørgensen; Christoph U Correll
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

2.  Service Use Following First-Episode Schizophrenia Among Commercially Insured Youth.

Authors:  Todd P Gilmer; Els van der Ven; Ezra Susser; Lisa B Dixon; Mark Olfson
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

3.  Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study.

Authors:  Kim S J Lao; Angel Y S Wong; Ian C K Wong; Frank M C Besag; W C Chang; Edwin H M Lee; Eric Y H Chen; Joseph E Blais; Esther W Chan
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

4.  Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans.

Authors:  Bárbara Nunes Krum; Airton C Martins; Libânia Queirós; Beatriz Ferrer; Ginger L Milne; Félix Alexandre Antunes Soares; Roselei Fachinetto; Michael Aschner
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

Review 5.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study.

Authors:  Kenneth K C Man; Shih-Chieh Shao; Nathorn Chaiyakunapruk; Piyameth Dilokthornsakul; Kiyoshi Kubota; Junqing Li; Nobuhiro Ooba; Nicole Pratt; Anton Pottegård; Lotte Rasmussen; Elizabeth E Roughead; Ju-Young Shin; Chien-Chou Su; Ian C K Wong; Yea-Huei Kao Yang; Edward Chia-Cheng Lai
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-11-13       Impact factor: 4.785

7.  Association of Low-Dose Quetiapine and Diabetes.

Authors:  Mikkel Højlund; Lars C Lund; Kjeld Andersen; Christoph U Correll; Jesper Hallas
Journal:  JAMA Netw Open       Date:  2021-05-03

8.  Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.

Authors:  Miquel Bernardo; Fernando Rico-Villademoros; Clemente García-Rizo; Rosa Rojo; Ricardo Gómez-Huelgas
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

9.  Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Métabolique à Long Terme des Jeunes Traités par Antipsychotiques de Deuxième Génération, Cinq ans Après la publication des Lignes Directrices Camesa: Faisons-Nous des Progrès?

Authors:  Sarra Jazi; Leila Ben-Amor; Pascale Abadie; Marie-Line Menard; Rachel Choquette; Claude Berthiaume; Laurent Mottron; Drigissa Ilies
Journal:  Can J Psychiatry       Date:  2020-11-26       Impact factor: 4.356

10.  Impacts of Psychopharmaceuticals on the Neurodevelopment of Aquatic Wildlife: A Call for Increased Knowledge Exchange across Disciplines to Highlight Implications for Human Health.

Authors:  Stephanie J Chan; Veronica I Nutting; Talia A Natterson; Barbara N Horowitz
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.